MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
14 Mayo 2024 - 2:19PM
MEACOR Inc. is pleased to announce the successful closing of its
$15 million Series A funding round. This substantial investment
supports MEACOR’s mission to offer a novel transcatheter approach
for the treatment of mitral and tricuspid valve regurgitation.
“This is a pivotal moment for MEACOR,” said Toufic Azar, CEO and
co-founder. “This funding round underscores the potential of our
technology to enhance valvular heart repair. With this capital, we
can strategically grow our team, to rapidly achieve critical
milestones while maintaining our lean and efficient R&D and
clinical operations.”
MEACOR’s proprietary technology, Cryocinch, is designed
to leverage on-demand cryoadhesion to compensate for cardiac
motion, enabling precise and reproducible implantation of
interconnected anchors along the valve annulus to effectively stop
regurgitation. This minimally invasive method, when
approved, could offer numerous patient benefits over traditional
open-heart surgery, including shorter recovery times, reduced
complication risks, and lower overall costs.
“Transcatheter annuloplasty remains an unmet frontier in the
management of valvular regurgitation, which to date has been
limited to valve replacement and edge-to-edge repair,” noted Dr.
Renzo Cecere, co-founder, President, and Chief Medical Officer of
MEACOR, and cardiothoracic surgeon at McGill University. “MEACOR’s
technology promises a reproducible, robust, and efficient
procedure. Cryoadhesion is designed to enhance ease of positioning
and stabilization of the annulus, providing significant advantages
for both doctors and patients.”
MEACOR is thrilled to welcome Dr. Azeem Latib and Dr. Susheel
Kodali, renowned key opinion leaders in interventional cardiology,
as senior clinical advisors. Additionally, Rick Geoffrion, a serial
entrepreneur in interventional cardiology devices, joins the team
as a senior business advisor.
About MEACOR
MEACOR is a privately held medical device company dedicated to
developing innovative solutions for minimally invasive heart valve
repair using groundbreaking transcatheter cryoadhesion technology
to significantly impact the lives of patients worldwide.
Contact: info@meacor.com